Search

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

A brand new EHA website!

You may already have noticed the new EHA look & feel.  We are proud to share it with you already.  We are currently migrating all our pages and related information.

Read more

Publications

During 2023 and 2024, the SWG on Pediatric Hematology contributed to the development of the EHA SIOPe Pediatric Extended Syllabus. This syllabus will be the basis for our future activities in the educational space.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies, scheduled to be held on October 18-20, 2024 in Tbilisi, Georgia.…

Read more

Call for interest

As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more